Discovery and optimization of nonpeptide HIV-1 protease inhibitors
Peter J. Tummino(Intarcia Therapeutics (United States)), Donald Hupe(Pfizer (United States)), A.G. Pavlovsky(Pfizer (United States)), Christopher Gajda(Pfizer (United States)), Thomas J. McQuade(University of Massachusetts Chan Medical School), Susan E. Hagen(Pfizer (United States)), Elizabeth A. Lunney(Pfizer (United States)), Edmund L. Ellsworth(Pfizer (United States)), Carolyn Nouhan(Pfizer (United States)), Neil M.H. Graham(UK Dementia Research Institute), Donna Ferguson(Pfizer (United States)), J. V. N. Vara Prasad(Pfizer (United States)), Kimberly S. Para(Pfizer (United States)), Bradley D. Tait(Pfizer (United States)), Stephen J. Gracheck(Pfizer (United States)), John M. Domagala(Pfizer (United States)), John W. Erickson(National Institutes of Health)
Cited by 29
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k